Teladoc Health Inc (NYSE:TDOC) posted upbeat results for the fourth quarter on Wednesday.The company posted a quarterly loss of 14 cents per share, versus market estimates of a loss of 18 cents per share. The company's sales came in at $642.269 million, beating estimates of $635.235 million.Teladoc Health said it sees FY2026 GAAP loss of $(1.10)-$(0.70) vs market estimates of $(0.76). The company expects sales of $2.470 billion-$2.587 billion, versus estimates of $2.548 billion.“We closed 2025 with a solid ...

Key Takeaways Teladoc Health reported a Q4 adjusted loss of 14 cents, narrower than estimates and year-ago loss.TDOC saw 19% international growth and 5% Integrated Care revenue growth, boosting results.BetterHelp revenues fell 6% in Q4, with 2026 guidance projecting further declines in the segment.Teladoc Health, Inc. (TDOC) reported a fourth-quarter 2025 adjusted loss of 14 cents per share, narrower than the Zacks Consensus Estimate of a loss of 19 cents. The company posted a loss of 28 cents in the year-a ...

Teladoc Health (NYSE:TDOC) shares are up on Thursday following the company’s latest earnings report, which highlighted a mix of revenue changes across its segments.The stock is moving higher as the broader market is experiencing a mixed day, with the Nasdaq down 1.57% and the S&P 500 down 0.87%, indicating that the positive movement in Teladoc may be driven by company-specific factors rather than overall market trends.Performance HighlightsTeladoc Health reported a quarterly loss of 14 cents per share, comp ...

Table of Contents x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 or Washington, D.C. 20549 _______________________________________________ Form 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 _______________________________________________ TELADOC HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION 155 E 44t ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAyush Vyas - Equity Research Associate - Healthcare Technology and Distribution, Healthcare Facilities, and Managed CareChuck Divita - CEODavid Roman - Managing Director and Co-Head Healthcare Business Unit - MedTech and Healthcare ITJailendra Singh - Managing Director - Healthcare Technology, Distribution and CROsMichael Minchak - Head of Investor RelationsRichard Close - Managing Director, Equity Research - ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsAyush Vyas - Equity Research Associate - Healthcare Technology and Distribution, Healthcare Facilities, and Managed CareChuck Divita - CEODavid Roman - Managing Director and Co-Head Healthcare Business Unit - MedTech and Healthcare ITJailendra Singh - Managing Director - Healthcare Technology, Distribution and CROsMichael Minchak - Head of Investor RelationsRichard Close - Managing Director, Equity Research - ...

Teladoc Health (NYSE:TDOC) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Speaker17Good afternoon. Thank you for attending today's Teladoc Health Q4 2025 earnings conference call. My name is Tamia, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass this, the conference over ...

4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 (“Fourth Quarter 2025”) and full year ended December 31, 2025 (“Full Year 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 (“Fourth Quarter 2024”) and full year ended December 31, 2024 (“Full Year 2024”). Highlights Fourth Quarter 2025 revenue of $642 ...

Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2025 Results NEW YORK, NY, February 25, 2026—Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended December 31, 2025 ("Fourth Quarter 2025") and full year ended December 31, 2025 ("Full Year 2025"). Unless otherwise noted, percentage and other changes are relative to the three months ended December 31, 2024 ("Fourth Quarter 2024") and full year ended December 31, 2024 ...